-
-
-
-
-
-
-
ONCOTELIC REPORTS Q2 2022 COMPARED TO Q2 2021 FINANCIAL RESULTS
-
-
-
-
-
-
-
ONCOTELIC TO ACQUIRE LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.
-
-
-
-
-
-
-
ONCOTELIC THERAPEUTICS, INC. ANNOUNCED SYNERGY BETWEEN OT-101 AND IL-2 (PROLEUKIN) AT AACR-2021
-
-
1,155,348 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

